Mark D. Young, Ph.D.

Head of CMC

Dr. Young has over 45 years of experience in the pharmaceutical development, with over 34 years in the area of biologics process development and manufacturing.  During his career, he has served at executive levels in five biotechnology companies with responsibility for process development, manufacturing, and quality.

Prior to joining Vitaeris, Dr. Young served as Senior Vice President, Pharmaceutical Development for Alder Biopharmaceuticals.  He trained as a Chemical Engineer, receiving his masters and doctoral degrees at Columbia University and the University of Michigan, respectively.

Vitaeris is now part of CSL Behring! We are pleased to become part of CSL Behring, a well-established, global industry leader, and know that the future of clazakizumab is in excellent hands. Together, we have already achieved much progress through our partnership over the past few years and are now in an even stronger position to realize our collective goal of addressing one of the greatest unmet needs in the organ transplant community.

Learn more